myirislogo
23 October, 2018 17:31 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Tata Motors 170.65 0.06
State Bank O 255.35 1.77
Icici Bank 321.70 1.62
Asian Paints 1138.80 5.21
I T C 285.90 0.82
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:524715NSE:SUNPHARMABloomberg:SUNP@INReuters:SUN.BO
Market Lot: 1Face Value: 1ISIN Demat: INE044A01036
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
18-SEP-18 Sun Pharmaceutical Industries today announced that Almirall has received the European Commission (EC) approval for ILUMETRI (tildrakizumab) for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy. 14-SEP-18 Sun Pharmaceutical Industries today announced U.S. Food and Drug Administration (USFDA) approval for the New Drug Application (NDA) of XELPROSTM (latanoprost ophthalmic ...   More..
Business Profile Future Plans
CEO Talk
Sun Pharma firmly believes in optimising returns on available resources. It now intends to extend this philosophy to the area of new drug discovery  Dilip Shanghvi
One To One
Recent news
Latest News
Sun Pharma gets European Commission nod for ILUMETRI  -IRIS 18-Sep-18
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2017(9)31-Mar-2017(12)31-Mar-2016(12)
Net sales 56715.9076501.8071743.20
Other Income9510.805144.102172.40
Total Income66226.7081645.9073915.60
Cost of goods sold60273.3079792.6079474.20
OPBDIT5953.401853.30-5558.60
PAT-6734.40-349.50-10733.60
Gross Block---
Equity capital--2406.60
EPS (Rs.)---
DPS (Rs.)---
BV (Rs.)---
P/E range (x)---
Debt / Equity (x)---
Operating margin (% of OI) 9.0 2.3-7.5
Net margin (% of OI)-10.2-0.4-14.5
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Sun Pharma Advanced Research Centre (SPARC)
Tandalja
Vadodara
Gujarat-390 020
PHONE
(0265) 5515 500/ 600
FAX
(0265) 2354 897
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer